Lacidipine Double-E Pharma

Lacidipine, the active ingredient in Lacidipine Double-E Pharma, is a calcium channel blocker (dihydropyridine) presented as a tablet for oral use. It treats hypertension in adult patients.\n\nGNH India supplies Lacidipine Double-E Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacidipine is a dihydropyridine calcium‑channel blocker used to manage high blood pressure by relaxing vascular smooth muscle.\n\n- Hypertension: lowers systolic and diastolic pressure, reducing cardiovascular risk.\n- Essential hypertension: provides sustained blood‑pressure control in primary hypertension.\n- Isolated systolic hypertension: improves pulse pressure in elderly patients with elevated systolic values.

Lacidipine may cause a range of adverse reactions, most of which are mild and reversible.\n\nCommon Side Effects:\n- Headache: mild to moderate intensity, often transient.\n- Flushing: warmth and redness, typically occurring shortly after dosing.\n- Peripheral edema: swelling of ankles or lower legs due to fluid accumulation.\n- Dizziness: sensation of light‑headedness, especially when standing quickly.\n\nSerious or Rare Side Effects:\n- Severe hypotension: marked drop in blood pressure that may cause fainting.\n- Hepatic dysfunction: abnormal liver enzymes or hepatitis.\n- Allergic reactions: rash, urticaria, or angioedema requiring immediate medical attention.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications.\n\n- Blood pressure monitoring: obtain baseline readings and reassess regularly after dose changes.\n- Renal impairment: use cautiously in patients with severe renal dysfunction; monitor renal function.\n- Hepatic impairment: consider dose adjustment in moderate to severe liver disease.\n- Concomitant antihypertensives: avoid excessive hypotension when combined with other blood‑pressure‑lowering agents.\n- Pregnancy and lactation: safety not established; avoid unless clearly indicated.\n- Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture.

Lacidipine can interact with several drug classes, altering its efficacy or safety profile.\n\nMajor Interactions (Avoid):\n- Potent CYP3A4 inhibitors: may raise lacidipine levels, increasing hypotension risk.\n- Co‑administration with other calcium‑channel blockers: additive vasodilation can cause severe hypotension.\n- Grapefruit juice: markedly enhances drug exposure, should be avoided.\n\nModerate Interactions (Monitor Closely):\n- Diuretics: may amplify antihypertensive effect; monitor blood pressure.\n- Beta‑blockers: combined effect on heart rate; watch for bradycardia.\n- NSAIDs: can diminish antihypertensive response and affect renal function; assess periodically.